We are live on ! Find out more
NVIV

InVivo Therapeutics Holdings Corp
NVIV

Delisted

NVIV was delisted on the 12th of February, 2024.

Back to rankings

16 hedge funds and large institutions have $673K invested in InVivo Therapeutics Holdings Corp in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

16% less funds holding

Funds holding: 19 → 16 (-3)

38% less capital invested

Capital invested by funds: $1.09M → $673K (-$414K)

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Holders
16
Holders Change
-3
Holders Change %
-15.79%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
4
Reduced
3
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$18.2K
2
UBS Group
UBS Group
Switzerland
+$4.77K
3
TRCT
Tower Research Capital (TRC)
New York
+$3.79K
4
Citigroup
Citigroup
New York
+$1.1K
5
State Street
State Street
Massachusetts
+$819

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$108K
2
VF
Virtu Financial
New York
-$58K
3
Jane Street
Jane Street
New York
-$21K
4
HF
HRT Financial
New York
-$11K
5
TSS
Two Sigma Securities
New York
-$8K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$299K – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$101K -$108K -11,394 -49%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$95K – – –
State Street
4
State Street
Massachusetts
$76K +$819 +86 +1%
Renaissance Technologies
5
Renaissance Technologies
New York
$27K +$18.2K +1,916 +153%
Northern Trust
6
Northern Trust
Illinois
$24K – – –
Two Sigma Advisers
7
Two Sigma Advisers
New York
$14K +$685 +72 +5%
Morgan Stanley
8
Morgan Stanley
New York
$10K -$10 -1 -0.1%
UBS Group
9
UBS Group
Switzerland
$9K +$4.77K +501 +99%
ICM
10
IMS Capital Management
Oregon
$7K – – –
Millennium Management
11
Millennium Management
New York
$4K -$5.84K -614 -57%
TRCT
12
Tower Research Capital (TRC)
New York
$3K +$3.79K +398 New
IA
13
IFP Advisors
Florida
$2K – – –
Royal Bank of Canada
14
Royal Bank of Canada
Ontario, Canada
$1K – – –
Citigroup
15
Citigroup
New York
$1K +$1.1K +116 New
VF
16
Virtu Financial
New York
– -$58K -5,040 Closed
Jane Street
17
Jane Street
New York
– -$21K -1,872 Closed
HF
18
HRT Financial
New York
– -$11K -982 Closed
TSS
19
Two Sigma Securities
New York
– -$8K -737 Closed
Bank of America
20
Bank of America
North Carolina
– -$29 -3 Closed

NVIV Hedge Fund Activity: Q1 2022 in Review

16 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in InVivo Therapeutics Holdings Corp (NVIV) for Q1 2022, worth a combined $673K — down 38% from $1.09M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of NVIV and 2 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 4 added.

The largest buyer was Renaissance Technologies, adding an estimated $18.2K. The largest seller was Vanguard Group, cutting an estimated $108K.

  • 16 institutional investors held InVivo Therapeutics Holdings Corp (NVIV) as of Q1 2022, down from 19 in Q4 2021.
  • Funds reported $673K of InVivo Therapeutics Holdings Corp stock for Q1 2022, down 38% quarter-over-quarter.
  • 2 funds opened new InVivo Therapeutics Holdings Corp positions in Q1 2022 and 5 closed out, a net change of -3 holders.
  • The largest InVivo Therapeutics Holdings Corp buyer in Q1 2022 was Renaissance Technologies, an estimated $18.2K added.
  • The largest InVivo Therapeutics Holdings Corp seller in Q1 2022 was Vanguard Group, an estimated $108K sold.

Based on aggregated 13F filings for Q1 2022.